Was betrifft es? Warum ist das wichtig?

Before participants can be recruited in a study, they have to:

  • Be pre-screened for study participation (e.g. comply with the study`s main inclusion and exclusion criteria)
  • Follow the defined informed consent process of the study
  • Sign the study`s Informed Consent Form (ICF), which confirms their agreement to participate in the study

 

Upon pre-screening, ongoing study specific screening is done after the participant has been informed about the study and has signed the ICF.

 

Screening incudes to:

  • Assess the participant`s patient file to ensure inclusion / exclusion criteria are met (e.g. diagnosis / healthy volunteers, disease stage, co-morbidities, medication intake, treatment naïve, blood analysis, age, gender)
  • Interview the participant regarding additional study criteria (e.g. current smoking- and drinking habits, intake of over the counter medications, activity / sleeping patterns, transport means and time at disposal)
  • Perform specific screening tests (e.g. pregnancy, infectious diseases, blood type)

Mehr

The SP-INV or Site-INV is responsible to ensure that participants are:

  • Unmistakably informed about the study and understand what it entails (e.g. risks and benefits, time investment, provision of biological material and health related personal data, administration of the investigational product (IMP / IMD)
  • Given ample opportunity to ask questions to make a sound decision
  • Given adequate time to decide
  • Informed regarding their right to withhold or revoke their consent at any time, without stating any reason
  • Informed that revoking consent has no bearings on ongoing or future medical treatment or care
  • Informed of results relating to their health in an appropriate manner. Be aware that they can abstain from receiving such information.

 

Neither SP-INV, Site-INV, nor the study staff, should coerce or unduly influence participants to participate or continue to participate in a study.

Was muss ich befolgen?

As a SP-INV and Site-INV, implement and comply with the study`s Informed Consent (IC) Process, such as to:

  • Document ICF tasks and responsibilities in a site delegation-log (who informs and recruits participants)
  • Ensure each participant is:
    • Provided with his/her personal ICF
    • Enters his/her name, gender, and date of birth 
    • Personally enters place, dates and signs the ICF (i.e. either in person or electronically)
  • As a Site-INV(s):
    • Enter name (legibly) and personally date and sign the ICF (i.e. after the participant either in person or electronically)
    • Document the time when ICF was obtained. This is especially important if study relevant procedures are planned the same day
    • Provides the participant with a signed copy of the ICF
    • Make a note in the patient file and the study database (e.g. CRF) confirming participant recruitment
  • File the ICF in the Investigator Site File (ISF)

Mehr

As a SP-INV and Site-INV do not:

  • Use an old outdated or unapproved ICF version (e.g. unapproved by Ethics Committee (EC))
  • Leave date and place empty or pre-enter date & place on behalf of the participant
  • Forget to make participant sign the ICF document
  • Personally forget to sign the ICF document
  • Have the ICF document signed by a non-authorised staff member (i.e. not listed on the site delegation-log)

 

Consent given in an electronic form is permissible provided that the chosen method:

  • Unmistakably identifies the study participant concerned
  • Prevents an overhasty decision
  • Is protected against modification

Wo kann ich Hilfe anfordern?

Your local Research Support Centre can assist you with experienced staff regarding this topic

  • Basel, Departement Klinische Forschung (DKF), dkf.unibas.ch

  • Lugano, Clinical Trials Unit (CTU-EOC), ctueoc.ch

  • Bern, Department of Clinical Research (DCR), dcr.unibe.ch

  • Geneva, Clinical Research Center (CRC), crc.hug.ch

  • Lausanne, Clinical Research Center (CRC), chuv.ch

  • St. Gallen, Clinical Trials Unit (CTU), h-och.ch

  • Zürich, Clinical Trials Center (CTC), usz.ch

External Links

Swissethics – in particular see

  • Time for consideration

References

ICH GCP E6(R3) – see in particular guidelines

  • Glossary: Definition Informed Consent
  • 2.8. Informed consent of Trial Participants

ISO 14155:2020 Medical devices (access liable to cost) - see in particular sections

  • 5.8 Informed consent
  • 10.5 Informed consent procedure

Swiss Law

HRA – see in particular article and chapter

  • Art. 7 Consent
  • Art. 8 Right to receive information
  • Chapter 2, section 2. Information and consent

ClinO – see in particular articles

  • Art. 7 Information given to participants
  • Art. 7c Form of consent (by hand or electronic)
  • Art. 8a Communication of results
  • Art. 9 Consequences of revocation of consent
  • Art. 15 Post hoc consent in emergency situations

ClinO-MD – see in particular article

  • Art. 3b Participant information and consent

HRO – see in particular articles and chapter

  • Art. 8 Information given to participants
  • Art. 8c Form of consent (by hand or electronic)
  • Art. 9a19 Communication of results
  • Art. 10 Consequences of revocation of consent
  • Art. 11 Research projects in emergency situations
  • Chapter 3, section 2. Informed consent and information in further use of biological material and health-related data
Abkürzungen
  • ClinO – Clinical Trials Organisation
  • ClinO-MD – Ordinance on Clinical Trials with Medical Devices
  • CTU – Clinical Trials Unit
  • HRA – Human Researcg Act
  • HRO – Human Research Ordinance
  • ICF – Informed Consent Form
  • ICH-GCP – International Council for Harmonisation - Good Clinical Practice
  • IMP/MD - Investigational Medicinal Product / Medical Device
  • ISF – Investigator Site File
  • ISO – International Organization for Standardization
  • Site-INV – Site-Investigator
  • SP-INV – Sponsor-Investigator
  • TMF – Trial Master File
Conduct ↦ Management ↦ Participant Recruitment ↦ Screening and Consent
Study
Basic

Provides some background knowledge and basic definitions

Basic Monitoring
Concept

Starts with a study idea

Ends after having assessed and evaluated study feasibility

Concept Statistic Methodology
Concept Drug or Device
Development

Starts with confidence that the study is feasible

Ends after having received ethics and regulatory approval

Development Drug or Device
Set-Up

Starts with ethics and regulatory approval

Ends after successful study initiation

Set-Up Ethics and Laws
Set-Up Statistic Methodology
Set-Up Quality and Risk
Set-Up Drug or Device
Conduct

Starts with participant recruitment

Ends after the last participant has completed the last study visit

Conduct Statistic Methodology
Conduct Drug or Device
Completion

Starts with last study visit completed

Ends after study publication and archiving

Completion Drug or Device
Current Path (click to copy): Conduct ↦ Management ↦ Participant Recruitment ↦ Screening and Consent